347 results on '"Amengual, Jennifer E."'
Search Results
2. Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma
3. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
4. How I treat posttransplant lymphoproliferative disorder
5. Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry
6. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
7. Isolated Optic Neuropathy as Presenting Sign of Systemic Lymphoma
8. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
9. Chromatin-Remodeled State in Lymphoma
10. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
11. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
12. Hypomethylating Agents in Lymphoma
13. Emerging EZH2 Inhibitors and Their Application in Lymphoma
14. Queen's gambit: response-adapted win in CAYA with cHL
15. Supplementary Figure 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
16. Supplementary Data from Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
17. Supplemental Figure 1 from Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
18. Supplemental Figure 1 from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
19. Video 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
20. The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
21. Therapeutic Options for Aggressive T-Cell Lymphomas
22. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma
23. Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder
24. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
25. The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation
26. Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
27. First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade
28. Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder
29. A Tet-a-Tet in T follicular helper cell lymphoma
30. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
31. Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
32. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
33. Murine models in mantle cell lymphoma
34. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma
35. Organ-specific toxicity of romidepsin in patients with preexisting cardiovascular disease: a retrospective analysis
36. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma
37. Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL
38. Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas
39. Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma
40. Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
41. Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL
42. Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma
43. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up
44. JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity
45. Outcomes in Minorities with PTCL By Clinical Trial Enrollment
46. Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes
47. First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL
48. The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder
49. Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
50. Isolated Optic Neuropathy as Presenting Sign of Systemic Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.